NCT00446862View on ClinicalTrials.gov

The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study

CompletedOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

June 30, 2012

Study Completion Date

December 31, 2012

Conditions
Fabry DiseaseProteinuria
Interventions
DRUG

enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers

10 mg by mouth every day; 25 mg by mouth every day

Trial Locations (6)

1

General Hospital Slovenj Gradec, Ljubljana

30322

Emory University, Atlanta

52242

University of Iowa, Iowa City

60614

Feinberg School of Medicine, Northwestern University, Chicago

35294-0006

University of Alabama at Birmingham, Birmingham

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT00446862 - The Fabrazyme® and Arbs and ACE Inhibitor Treatment (FAACET) Study | Biotech Hunter | Biotech Hunter